Dihydroartemisinin

SKU: orb1310451

Description

Dihydroartemisinin (Artenimol) is the active metabolite of artemisinin and a potent antimalarial agent. It is widely used in malaria research, demonstrating efficacy in both in vitro parasite inhibition assays and in vivo animal models of infection.

Research Area

Cell Biology, Infectious Disease & Virology, Signal Transduction

Key Properties

• CAS Number: 71939-50-9
• MW: 284.35
• Purity: 99.72% (May vary between batches)
• Formula: C₁₅H₂₄O₅
• SMILES: C[C@@H]1[C@]2([C@]34[C@@](O[C@](C)(OO3)CC[C@]4([C@H](C)CC2)[H])(O[C@@H]1O)[H])[H]
• Target: Apoptosis,Autophagy,Parasite,NF-κB
• Solubility: DMSO:52.5 mg/mL (184.63 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:9 mg/mL (31.65 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.2 mg/mL (18.29 mM)

Bioactivity

• Target IC50:
  HGC-27 cells viability:5.608 μM (48h)|SGC-7901 cells viability:5.191 μM (48h)|HeLa cells proliferation:24.74 ± 0.38 μM
• In Vivo:
  METHODS: To study the antitumor activity of Dihydroartemisinin, an orthotopic CRC mouse model of HCT116 cells or a xenograft mouse model of DLD-1 cells was administered with Dihydroartemisinin (15 mg/kg, 45 mg/kg). RESULTS: In an orthotopic CRC mouse model of HCT116 cells, Dihydroartemisinin administered at a dose of 15 mg/kg or 45 mg/kg significantly inhibited tumor growth starting from the 18th day of treatment. In a xenograft mouse model of DLD-1 cells, Dihydroartemisinin significantly reduced tumor volume and weight. METHODS: To study the immunomodulatory effect of Dihydroartemisinin, healthy BALB/c mice were treated with Dihydroartemisinin (0.1 mg/mL) by gavage for 26 days. RESULTS: Dihydroartemisinin significantly up-regulated c-Fos expression in plasma cells and regulatory T cells (Treg).
• In Vitro:
  METHODS: Ovarian cancer cell lines ES2 and A2780 were treated with Dihydroartemisinin (0, 2.5, 5, 10, 20, 50, 100, and 200) for 48 hours, and the cell viability was detected by MTT assay. RESULTS: Dihydroartemisinin inhibited the growth of ES2 (IC50=8.77 ± 1.23 µM) and A2780 cells (IC50=8.77 ± 1.23 µM). METHODS: Glioblastoma cell lines U87 and U251 were treated with Dihydroartemisinin (0.2, 2, 20, 50, 100, 200 and 600 µmol/L) for 24, 48, and 72 hours, and the cell viability was detected by CCK-8 assay. RESULTS: Dihydroartemisinin inhibited the growth of U87 cells (IC50 values of 11.26 µM, 7.42 µM and 5.77 µM at 24, 48 and 72 hours, respectively) and U251 cells (IC50 values of 11.67 at 24, 48 and 72 hours, respectively) µM, 7.55µM, and 5.83µM). METHODS: Colorectal cancer cell lines SW620, DLD-1, HCT116, and COLO205 were treated with Dihydroartemisinin (0.2, 2, 20, 50, 100, 200, and 600 μmol /L) for 24 hours, and the cell viability was detected by MTT assay. RESULTS: Dihydroartemisinin inhibited the proliferation of SW620 cells (IC50=35.96 ± 8.76 µM), DLD-1 cells (IC50= 15.08 ± 1.70 µM) and HCT116 cells (IC50=19.53 ± 1.24) µM), COLO205 cells (IC50=38.46 ± 4.15 µM).
• Cell Research:
  BxPc3-RFP cells (3.5×104cells/well) were seeded in poly D-lysine-coated black, μClear 96-well plates with 0.2 ml medium. After 24 h, the cells were treated with dimethyl sulfoxide (DMSO) (control) or different concentrations (2.5, 10, 40, or 80 μM) of DHA dissolved in DMSO for 24, 48, and 72 h. At each time point, the fluorescence intensity emitted from cells was measured. (Only for Reference)

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

beta-Dihydroartemisinin, Dihydroartemisinin, Dihydroqinghaosu, DHA, b-Dihydroartemisinin, Artenimol, Autophagy, Apoptosis, Parasite, NFκB, NF-kB, NFkB, NF-κB, β-Dihydroartemisinin

Compound Identifiers

PubChem CID

3000518